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Lung transplantation is the only definitive therapy for many forms
of end-stage lung diseases. However, the success of lung transplanta-
tion is limited by many factors: (1) Too few lungs available for trans-
plantation due to limited donors or injury to the donor lung; (2 )
current methods of preservation of excised lungs do not allow
extended periods of time between procurement and implantation;
(3 ) acute graft failure is more common with lungs than other solid
organs, thus contributing to poorer short-term survival after lung
transplant compared with that for recipients of other organs; (4 )
lung transplant recipients are particularly vulnerable to pulmonary
infections; and (5 ) chronic allograft dysfunction, manifest by bron-
chiolitis obliterans syndrome, is frequent and limits long-term sur-
vival. Scientific advances may provide significant improvements in
the outcome of lung transplantation. The National Heart, Lung, and
Blood Institute convened a working group of investigators on June
14–15, 2004, in Bethesda, Maryland, to identify opportunities for
scientific advancement in lung transplantation, including basic and
clinical research. This workshop provides a framework to identify
critical issues related to clinical lung transplantation, and to delin-
eate important areas for productive scientific investigation.
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The transplantation of organs offers the promise of life-saving and
life-enhancing therapy for a variety of ailments. Lung transplanta-
tion (LTx) has become an acceptable therapy to palliate patients
with a variety of end-stage lung diseases. However, lung trans-
plantation has not turned out to be a panacea for chronic lung
disease because of significant limitations in the entire transplant
process (Figure 1). First, there are not nearly enough suitable
donor lungs to meet the needs of all patients with end-stage lung
disease. As a result, more patients die waiting for transplants than
from mortality associated with a lung transplant. Second, early
graft survival after LTx is worse than for other types of organs
transplanted (1). Finally, late survival after successful LTx is
hampered by the development of chronic allograft dysfunction
and by the life-limiting complications associated with conven-
tional immunosuppressive medications. Two factors impede
progress to address these problems: (1) lung transplant centers
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lack the infrastructure to facilitate prospective, multicenter clini-
cal studies of sufficient power to address clinical questions and
(2) there are too few investigators studying the biology of lung
transplantation.
The NHLBI convened a workshop on June 14–15, 2004, to
better understand these complex problems and to identify strate-
gies to address these and prioritize them. The topics addressed
by participants were wide-ranging. They included the following:
lung use rates from conventional brain-dead organ donors; safe
limits for donor lung function; consideration of the use of lungs
from non–heart-beating donors (NHBDs); ischemia-reperfusion
injury (IRI); other causes of primary graft dysfunction; the host
immune response to a lung graft; the consequences of current
toxic immunosuppressive drugs, including infection and malig-
nancy; the discouraging incidence of bronchiolitis obliterans syn-
drome (BOS) as a manifestation of chronic allograft dysfunction;
and mechanisms associated with development of BOS. These
discussions required input from a variety of disciplines, including
lung transplant clinicians and experts in inflammation, immunol-
ogy, infectious disease, biology of structural matrix, pulmonary
epithelium and endothelium, and pharmacology. This article
summarizes these discussions and attempts to identify key issues
that should be the focus of future research in lung transplanta-
tion.
INADEQUATE NUMBER OF LUNGS FOR TRANSPLANT
There are many obstacles to organ donation, resulting in a re-
duced number of actual organ donors among the potential pool
of brain-dead individuals. There are large differences in organ
donation consent rates based on geographic area, cultural back-
ground, ethnicity, and age (2). In general, the level of lung procure-
ment and transplantation has leveled off (Figure 2), providing an
inadequate pool of transplantable lungs from deceased donors
and providing an impetus to alternative sources of organs. The
Division of Transplantation of the Health Resources and Ser-
vices Administration, part of the Department of Health and
Human Services, is beginning to address these issues (3). Unfor-
tunately, there are even fewer suitable lungs than other solid
organs among deceased donors because of lung injury from a
combination of the high incidence of aspiration (4), neurogenic
pulmonary edema (5), nosocomial infection, lung contusion, and
acute respiratory distress syndrome/acute inflammation in trauma
patients who become donors. Because each of these factors may
adversely affect the outcome of lung transplantation, there is reluc-
tance among lung transplant surgeons to use grafts from donors
that may function poorly. The net result is a growing disparity
between the number of candidates listed for transplantation
and the number of transplants performed in the United States
(Figure 2).
In the lung transplant community, there is considerable con-
troversy over the specific characteristics of an acceptable donor/
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Figure 1. Conceptual representation of the survival curve for prospec-
tive transplant patients before and recipients after lung transplant (LTX).
This figure illustrates that survival rates decline for patients with end-
stage lung disease pretransplant (pre-tx), and that the rate of decline
is only impacted moderately after transplantation (post-tx).
organ, and there is an ongoing effort to establish a classification
system of lung donors to help determine the limits of acceptability
while expanding the pool of available organs. There are substantial
differences among organ procurement organizations in lung re-
trieval rates and among transplant programs in lung use rates.
Options to increase the number of lungs available for transplant
include encouraging adoption of more uniform, and evidence-
based, policies by the Organ Procurement and Transplant Net-
work, such as requirements to always offer potentially suitable
lungs to transplant centers, to educate organ procurement orga-
nizations with poor lung retrieval rates, and to sanction organ
procurement organizations consistently below acceptable per-
formance standards. Such policies are under consideration by the
United Network for Organ Sharing Thoracic Organ Committee.
The number of lung transplants being performed in recent years
has increased only minimally, despite the increasing utilization of
more “marginal” donors (3, 6, 7). Regardless of efforts made to
maximize consent and retrieval rates from conventional donors,
the number of lungs and other organs remains inadequate to
meet the demand. According to Langone and Helderman (8),
“Even in a utopian situation in which consent was obtained for
all potential donors so that all potential organ donations were
retrieved, there would be an inadequate number to satisfy our
country’s current and future needs.” Xenotransplantation offers
the promise of an unlimited supply of donor organs, but the
immunologic barriers and potential infectious risks have not yet
been overcome (9–12). The working group and NHLBI made
a decision to exclude discussion of lung xenotransplantation from
this workshop.
Living-donor transplantation poses greater challenges in lung
recipients compared with kidney and liver recipients. The mor-
bidity and mortality associated with donor pneumonectomy pose
significant ethical considerations. Bilateral, living, lower lobe
transplants have been established as an acceptable alternative
at some centers (8, 13, 14), but size constraints and the require-
ment for two donors for each recipient preclude widespread use
of this procedure and limit the impact on the present shortage
of donor lungs (15).
Interest is growing in the prospect of using lungs from deceased,
circulation-arrested individuals, known as NHBDs. Before the
concept of brain death was introduced, all lung transplants were
performed using lungs retrieved quickly from circulation-arrested
donors. Since brain death was introduced and widely accepted
in North America and Europe in the early 1980s, virtually all
lung transplants have been performed using organs retrieved
from circulation-intact, brain-dead organ donors. Considerable
experience with transplantation of kidneys retrieved from NHBDs
is being accrued, with reports of equivalent or better long-term
Figure 2. Lung transplant patients waiting at years’ end (open bars),
patients undergoing lung transplant (hatched bars), and lung transplant
patients dying while waiting (black bars), by year. Adapted by permission
from Reference 3.
function of kidneys from NHBDs compared with conventional
heart-beating donors (16, 17). A much smaller experience exists
with liver transplants from NHBDs (16, 18, 19). Perceived limita-
tions on warm ischemic time led to the classification of NHBDs
into four categories, defined at the Maastricht conference in 1995
(20). The largest number of NHBDs are individuals who die
outside of the hospital or arrive dead to the emergency service
(Maastricht category I), and it is likely that few of these have
kidneys or a liver that are salvageable for transplant.
However, there is some evidence that lung tissue remains
viable for prolonged periods after circulatory arrest (21), an idea
that is supported by the routine culture of airway epithelial cells
from morgue specimens (22). There is considerable evidence in
animal models that lungs may function adequately after trans-
plantation even when retrieved hours after death (23). Variabil-
ity in donor conditions and in warm ischemic times inherent in
lung retrieval from individuals who arrive dead or who die in
emergency rooms mandates that a reliable method be developed
to predict function of lungs procured from human NHBDs. In
renal grafts from NHBDs, pump perfusion has enhanced post-
transplant graft function and also provided a rough measure
(flow and resistance) of the expected function of the grafts after
implantation. The development of comparable assays for lungs
poses logistic and mechanical challenges; the feasibility of as-
sessing gas exchange and circulation ex vivo has been demon-
strated in porcine experiments (24, 25) and also performed with
human lungs (26) (D. E. Van Raemdonck, personal communica-
tion, 2003; T. M. Egan, personal communication). Recently, Var-
ela (27) has performed in vivo gas exchange evaluation in NHBDs
to select lungs for transplant. If lungs can be retrieved from
NHBDs and substantial numbers can be used for transplant,
the shortage of lungs could be reduced. Ex vivo perfusion and
ventilation for assessment of lung function also offers an oppor-
tunity for manipulation of the graft that may enhance perfor-
mance post-transplant (28, 29).
If the number of lungs for transplant were unlimited, many
more lives could be enhanced or extended, and progress would
be accelerated in other areas of investigation, including clinical
studies of the mechanisms underlying acute lung injury and
chronic allograft dysfunction/BOS. In addition, indications for
lung transplantation might be extended to individuals who cur-
rently are not considered candidates due to the organ shortage.
EARLY GRAFT DYSFUNCTION
The in-hospital survival after LTx is poorer than for other solid
organs, as reflected in the 3-month survival of lung recipients of
85% (3). The two main reasons for this poor survival are early
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graft dysfunction and infection, and frequently the two clinical
conditions coexist. Early graft dysfunction may be impacted by
the condition of the donor lung. For example, data from Fisher
and colleagues (30) indicate that high levels of interleukin 8
(IL-8) in the donor lung was a key risk factor for early graft
dysfunction. In those patients, increased levels of IL-8 in the
donor lung were associated with increased levels of neutrophils
and worse oxygenation post-transplantation. Infection in the recip-
ient may be related to contamination of the donor graft, pre-
existing infection in the recipient (as in cystic fibrosis), or nosoco-
mial infection while intubated after surgery, and is aggravated by
the need for potent immunosuppression after transplant. Early
graft dysfunction is attributed to IRI, but there is little relationship
between death due to early graft failure and the duration of
ischemic time, except for that in older donors (31).
Understanding of the mechanisms contributing to IRI after
lung transplantation would allow the interruption of these patho-
logic effector mechanisms and reduce the incidence of primary
graft failure. Early graft injury also contributes to the risk for sub-
sequent episodes of rejection and perhaps even lymphocytic
bronchitis and bronchiolitis obliterans (32). A better understand-
ing of lung IRI would facilitate the use of lungs from NHBDs to
alleviate the donor shortage. Endothelial cells and mononuclear
phagocytes are likely cellular mediators of lung IRI. Pulmonary
macrophages have a major role in the elaboration of cytokines
that contribute to IRI (33, 34). Although studies applying large-
scale genomic technologies to lung IRI are preliminary, experi-
ments using gene arrays suggest that hundreds of genes demon-
strate up- or downregulation after reperfusion of transplanted
lungs in both humans and rats (35, 36).
The pulmonary vasculature is a dynamically regulated, semi-
permeable barrier to the lung interstitium and epithelial surface
of the alveolar membranes. Pulmonary endothelial cells serve
as gatekeepers to trafficking inflammatory and immune cells.
Profound vascular leak is a central component of the physiologic
derangement that occurs in IRI; this provides a rationale to focus
on the role of the pulmonary endothelium in the pathophysiology
of IRI. Given the importance of hypoxia in organ procurement
and reimplantation, the phenotypic changes of endothelial cells
during oxygen deprivation have been investigated. Surprisingly,
it is not even clear that hypoxia is a significant component of lung
graft ischemia given that lungs are frequently retrieved from
donors who have been ventilated with 100% oxygen. Neverthe-
less, hypoxia is associated with a decline in intracellular cAMP
levels (37). As a consequence, endothelial cells retract from
one another, promoting edema formation (38). Also, subjacent
vascular smooth muscle cells increase their tonus (i.e., become
vasoconstricted) (39). Endothelial cells become proadhesive for
circulating leukocytes, and leukocytes and platelets tend to ag-
gregate in microvessels. Supplementing deficient cyclic nucleo-
tide signaling systems can prevent some of these changes after
lung implantation (40).
After ischemia-reperfusion or transplantation, there are early
changes in the endothelial cell cytoskeleton. Abutting edges
between endothelial cells contract, resulting in gaps in the endo-
thelial cell monolayer. Selective filtration mediated by the mono-
layer is abrogated, leading to mass transport of fluid and solutes
into the alveolar space. The cells undergo many phenotypic and
functional changes that facilitate injury (reviewed in References
41, 42). For example, glycoprotein adhesion receptors are strongly
expressed on endothelium, and Weibel-Palade bodies undergo
exocytosis (43). P-selectin is translocated to the endothelial sur-
face, transcription of E-selectin increases, and expression of in-
tracellular adhesion molecule 1 is upregulated (44). These events
contribute to leukocyte diapedesis across the endothelial mono-
layer and tissue inflammation. Complement activation occurs early
in lung ischemia and reperfusion (45), and contributes directly to
injury both by a local deposition of the membrane attack com-
plex as well as by release of circulating anaphylotoxins, C3a and
C5a. Nitric oxide (NO), which is produced in abundance in the
normal lung vasculature, is rapidly quenched by reactive oxygen
species, such as superoxide (46). As a consequence, the homeo-
static mechanisms normally maintained by NO are disrupted.
Subsequently, there is thrombosis and leukostasis in the inflamed
postischemic lung graft. Early expression of transcriptional medi-
ators, such as early growth response gene 1 (Egr-1), as well as
AP1 and nuclear factor-B can also contribute to the inflamma-
tory and procoagulant milieu seen early on after lung transplanta-
tion (47).
Depletion of pulmonary macrophages resulted in substantial
reduction of lung IRI and improved graft function after trans-
plantation (33, 48). Proinflammatory cytokines, such as IL-1,
tumor necrosis factor  (TNF-), and IL-6 play a pivotal role
in IRI and cellular trafficking (49). These effects are modulated
by the elaboration of antiinflammatory cytokines IL-4 and
IL-10 (50). The balance of proinflammatory and antiinflamma-
tory cytokines in lung allografts may predict primary graft dys-
function (51). IRI also has profound effects on extracellular
matrix biology that is poorly understood, inducing injury repair
mechanisms and regeneration, through pathways presumably that
could be manipulated with therapeutic intent.
There are a number of strategies that have been shown to
mitigate lung IRI after experimental transplantation. These can be
broadly viewed as those in which normal homeostatic signaling
mechanisms are bolstered, transcription is modulated, chemical
reactions are inhibited, and inflammation or coagulation is sup-
pressed. Specific strategies include delivery of antioxidants, -ago-
nists, or cAMP- or cyclic guanosine monophosphate–enhancing
agents. For example, transcriptional blockers, such as antisense
Egr-1, administered during the preservation period prevent both
coagulant and leukoadhesive events after lung transplantation
(47). Other strategies to block leukoadhesion or coagulation
have also been used successfully in the setting of experimental
lung transplantation (44, 52).
Endothelial barrier protective strategies include hepatocyte
growth factor (53) inhibitors of endothelial myosin light-chain
kinase activity (54, 55), oxidized phospholipids (41, 54–56), and
the statins or hydroxymethylglutaryl-coenzyme A coreductase in-
hibitors (41, 54–58). Sphingosine 1-phosphate, a platelet-derived
phospholipid growth factor, is involved in both angiogenesis and
vascular hemostasis (59, 60) and recently has been shown to
prevent lung edema in models of LPS-induced lung injury (61)
and ventilator-induced lung injury (62).
Gene transfer strategies may be uniquely suited to address
IRI after lung transplantation, because IRI is a short-lived injury
that may not require prolonged gene expression, a problem that
plagues the clinical application of other gene transfer strategies.
Also, the ability to selectively transfect the lungs via the airway
without systemic transfection is unique to the lung. In a proof-
of-concept experiment, IRI was reduced in a rodent lung trans-
plant model by gene transfer of the antiinflammatory cytokine
IL-10 (63, 64), which modifies the environment of the transplanted
lung by reducing inflammation and promoting apoptosis rather
than necrosis (65). Endothelial NO synthase augmentation by
gene transfer is another strategy that has been successful (65,
66). To circumvent the potentially deleterious inflammatory ef-
fects of adenoviral vectors, administration of conjugates of the
free radical scavenging enzyme catalase to anti–platelet/endothe-
lial cell adhesion molecule-1 antibodies successfully localized the
enzyme to the pulmonary endothelium and reduced IRI after
experimental lung transplantation (67). This is another potential
strategy to target agents to the pulmonary endothelium.
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Although not fully elucidated, IRI may contribute to rejection
episodes through generation of novel antigens. For example, IRI
may release novel antigens from the interstitium of the lung graft
or alter the structure/function of molecules that under normal
conditions contribute immune homeostasis in the lung. Accord-
ingly, addressing IRI may have far reaching effects on the overall
health of the lung graft.
In summary, it is unlikely that a single strategy will succeed
as the one to trump all others in reducing lung IRI. However,
understanding each possible unique contributing mechanism may
help unravel clues toward the possibility of inhibiting common
pathologic pathways. The goal of this approach would be to reduce
early morbidity and mortality from the lung transplant procedure,
and potentially facilitate the use of lungs retrieved from NHBDs,
and to modify later immunology of the rejection response.
IMMUNOLOGY OF THE HOST RESPONSE: ACUTE AND
CHRONIC REJECTION
Acute and chronic rejection are causes of significant morbidity
and mortality. In-depth discussions and reviews of these processes
have been reported recently (68, 69). The current section will
provide a brief overview with an emphasis on those areas in need
of greater investigation.
During the alloimmune response, T cells recognize foreign
major histocompatibility complex (MHC) antigens by two dis-
tinct pathways of direct and indirect allorecognition. The direct
pathway is important in the vigorous alloimmune response seen
early post-transplantation when abundant donor-derived anti-
gen-presenting cells are present within the graft. Indirect allo-
recognition may also occur when processed host antigen-present-
ing cells present donor allopeptides; this pathway is responsible
for development of T-helper cells that promote alloantibody
production and possibly obliterative bronchiolitis (OB). OB is
the histologic hallmark of chronic allograft rejection in trans-
planted lungs and OB remains the single most important problem
limiting the long-term survival of the graft and recipient. OB
presents clinically with progressive dyspnea and airflow obstruc-
tion. The term “bronchiolitis obliterans syndrome” is used to
define the clinical problem of chronic rejection without histologic
proof of OB (70).
Acute rejection is characterized by two key histologic find-
ings: perivascular infiltration of mononuclear cells and by an
influx of CD4 and CD8 lymphocytes and macrophages into
the subepithelial layer of the airway forming a lesion known as
lymphocytic bronchiolitis; this appears to be a harbinger of OB/
BOS (71, 72). A fibroproliferative phase develops later in the
airways in which macrophages and myofibroblasts predominate.
Cytokines (TNF-, IL-1, IL-6, IFN-, and IL-2) have been
implicated in the pathogenesis of OB/BOS (71–76). The regula-
tory cytokines IL-12 and IL-10 also likely play a key role in this
process, but have not been studied in detail. Although much
work has been done in allografts other than the lung, there is
a lack of information regarding allorecognition networks and
cytokine pathways involved in lung allograft rejection.
Chemokines in the Rejection Response
The predominant function of chemokines is to induce the migra-
tion and activation of leukocytes, including neutrophils, mono-
cytes, lymphocytes, eosinophils, and dendritic cells (77). Leuko-
cyte chemotactic and activating effects of chemokines are vital
to the development of effective host response to an “antigen”
(i.e., xeno-, allo-, autoantigens) and the subsequent shift from
innate to polarized adaptive immunity with the generation of
a predominance of T-helper (Th) type 1 versus Th2 cytokine
expression within the local microenvironment. Moreover, chemo-
kines have broad effects on other facets of lung allograft rejection
related to homeostasis, inflammation, and fibrosis.
Studies indicate that chemokines play a major role in directing
alloantigen-primed T cells and other effector leukocytes into grafts
to mediate rejection (78, 79). During the rejection of allografts
in rodent models, the production of chemokines in grafts occurs
in two temporal cascades. Chemokines in the first cascade appear
shortly after reperfusion and at equivalent levels in iso- and
allografts and include chemokines directing the recruitment of
cellular components of the innate immune system (e.g., neutro-
phils, macrophages, and natural killer cells). These chemokines
are induced in response to the surgical trauma to tissue and IRI
imposed on the graft. Studies show attenuation of early inflamma-
tion and tissue damage during reperfusion of ischemic organs,
including allografts, by interfering with the activity of neutrophil
chemoattractants (52). This strategy might be useful in promoting
long-term survival of allografts.
The second chemokine cascade begins as the early cascade
subsides, and occurs only in allografts. These chemokines direct
recruitment of alloantigen-primed T cells and other effector leuko-
cytes into the allograft (80–82). These chemokines include the
CXCR3 ligands and the CCR5 ligands. Antagonism of CXCR3,
CCR5, and their respective CCR5 ligands can attenuate recruit-
ment of primed T cells and other effector leukocytes trafficking
into allografts and prolong allograft survival (81). In addition to
their chemoattractant properties, chemokines may also influence
the level and phenotype of T-cell priming. The presence of spe-
cific CCR5-binding chemokines in the lymphoid tissue draining
the graft supports a model of chemokine-mediated regulation
of alloreactive T-cell priming in response to the allograft. Collec-
tively, these studies indicate diverse and complex functions of
chemokines regulating recipient immune responses to allografts.
Indeed, IL-8 (neutrophil chemotaxis), the C-C chemokines
(RANTES [regulated on activation, normal T-cell expressed and
secreted], macrophage inflammatory protein 1, macrophage
inflammatory protein 1), and the IFN-–induced chemokines
(interferon-–inducible 10kd protein, interferon-induced mono-
kine, and interferon-inducible T-cell alpha chemoattractant) all
have been implicated in the pathogenesis of OB/BOS in both
human and animal studies (80, 82, 83). Because chemokines have
key roles in trafficking, remodeling, and priming immune re-
sponses, more study is required to understand the function of
these critical molecules in lung transplantation in general, and
OB in particular.
Autoimmunity, Regulatory T cells, and Tolerance
A clear role for alloimmunity in the pathogenesis of the rejection
response has been documented in many studies. An ideal ap-
proach to preventing rejection would be to introduce a state of
tolerance to the graft rather than generalized suppression of ac-
quired immunity. The cells that mediate or regulate tolerance
to allografts are the same cells that mediate tolerance to self-
antigens. Accordingly, loss of tolerance to alloantigens could also
predispose an individual to autoimmunity. In turn, autoimmunity
could participate in the rejection response (84–87). Release of novel
self-antigens could result from repeated acute rejection episodes
in which sequestered self-antigens are released after a cycle of
damage and repair. For example, collagen V, a highly conserved
self-antigen sequestered in the perivascular and peribronchial
spaces of the lung, is released into the transplanted lung after
IRI or after rejection episodes (87). This may account for the
presence of collagen V–specific T cells isolated from rat lung
allografts during rejection (87, 88). The role of collagen V reac-
tivity in the rejection response is highlighted by reports showing
that collagen V–specific T cells induce rejection-like disease in
rat isograft lungs (87), and that human lung transplant recipients
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who develop immunity to collagen V are at greater risk for graft
loss and development of OB (W. Burlingham and D. S. Wilkes,
unpublished manuscript).
Regulatory T cells (Tregs) are CD4CD25 cells that func-
tion to suppress auto- and alloimmune responses. Developing
an immune response to self- and alloantigens implicates that
Treg dysfunction occurs during lung allograft rejection. Data are
limited regarding the role of Tregs in lung transplant rejection.
One report in humans indicates that the rejection response and
OB were associated with fewer numbers of CD4CD25 T cells
(89). These cells are believed to mediate immune suppression in a
contact-dependent manner by membrane-associated transforming
growth factor  (TGF-). Therefore, for Tregs to mediate suppres-
sion, the responding cells should be permissive to TGF-–mediated
signaling. Evidence for this is a report showing that pathogenic
autoreactive cells isolated from rat lung allograft recipients did
not express SMAD7 transcripts, a key negative regulator of
TGF- signaling (88).
Common pharmacologic mediators used to prevent rejection
may actually diminish protective tolerance. Modulation of intra-
cellular calcium levels by calcineurin is a major mechanism of
immunosuppressive drugs, such as cyclosporine and FK506. Cal-
cineurin inhibitors suppress IL-2 transcription. Although suppres-
sion of IL-2 has been documented to downregulate alloimmune
responses, it may cause a breach of tolerance. Treg function is
dependent on IL-2. As initially suggested by other investigators,
perhaps immunosuppressive drugs that interfere with IL-2 have
detrimental effects on Tregs and the development of tolerance
to transplanted organs (90). Therefore, because Tregs function
to suppress immune responses to self-antigens, calcineurin inhib-
itor–induced suppression of Treg function could precipitate the
autoimmune responses observed during lung allograft rejection.
These data highlight the need for a better understanding of the
properties of current treatment regimens in organ transplanta-
tion, including lymphocyte depletion strategies, to prevent ad-
verse immune responses and to promote tolerance induction. In
addition, there is a great need for in-depth analysis of interaction
of allo- and autoimmunity in the rejection response, and the
roles of Tregs in the modulation of OB.
Humoral Immunity
Although much attention has been focused on cellular immunity
that could mediate OB, recent evidence suggests that humoral
events may also be involved. For example, the presence of anti-
HLA antibodies was associated with steroid-resistant allograft
rejection and increased soluble C4d as measured in bronchoal-
veolar lavage (BAL) (91, 92). Detection of C4d, a component of
the complement cascade, is a strong indicator of active humoral
immunity. HLA antibodies develop in a significant proportion
of lung transplant recipients (25%), predominately in the first
year (91). Anti-HLA antibodies are associated with an increased
frequency of refractory acute rejection in the first 6 months, and
with a higher prevalence of BOS in the late post-transplant
period (91). During acute cellular rejection, there is an increased
ratio of IgG2/IgG1 within the lung allograft, suggesting local
upregulation of Th1 activity (93). Although non–complement-
fixing antibodies can activate bronchial epithelial cells by cross-
linking antigens (94), recent studies in transplants other than
the lung implicate complement activation in the pathogenesis
of rejection. For example, systemic activation of complement by
cobra venom in rats causes pulmonary vascular leakage that can
be prevented by blocking C5a (95). Parallel findings have been
reported for complement activation by ischemia-reperfusion of
limbs, cardiopulmonary bypass, and sepsis. OKT-3 activates com-
plement (96) and can also cause an accumulation of neutrophils
in pulmonary capillaries that might be confused with “capillar-
itis” (97). Indeed, reports from several groups using microarrays
in a rodent model indicate that antibody and complement genes
are upregulated in the transplanted lung (45, 98, 99). These data
are similar to prior reports from other investigators (45, 98).
Antibody-producing plasma cells can be identified by immuno-
histology in transplanted lungs. Because macrophages and epi-
thelial cells are sources of complement, both immune cells (e.g.,
macrophages) and traditionally nonimmune cells (e.g., epithe-
lium) could contribute to the pathogenesis of BO. However, the
incidence of antibody/complement-mediated injury to lung trans-
plants is unknown, and the primary cause of complement activa-
tion in the lung has not been established. Finally, the target anti-
gens of the locally produced antibodies have not been fully
identified.
Innate immune mechanisms. In recent years, the complexity
and central importance of innate immunity in host defense have
been recognized. In contrast to adaptive immunity, which relies
on highly specific B- or T-cell receptor interactions with foreign
antigen presented in the context of host MHC, the secreted cellular
and intracellular components of host innate defense recognize
and respond to pathogen-associated molecular patterns (PAMPs).
These PAMPs represent molecular structures highly conserved
among large classes of microbial pathogens, not present in the
host. Endotoxin, or LPS, for example, is a prototypic trigger of
innate immunity commonly found on gram-negative bacteria. Cel-
lular components of innate immunity, such as macrophages and
dendritic cells, rely on the Toll-like receptors (TLRs) to recog-
nize PAMPs. Currently, 11 TLRs have been identified (100),
most associated with recognition of distinct PAMPs.
Activation of specific innate immune pathways through TLRs
is now recognized as critical to the development of adaptive im-
mune responses. Important effects on adaptive immunity include
differentiation of dendritic cells, upregulation of MHC, upregu-
lation of costimulatory molecules (e.g., CD80 and CD86), and
production of various chemokines and cytokines (101). The pres-
ence of appropriate costimulation is essential for naive T cells
to develop an allo-specific response (i.e., clonal expansion) to a
foreign peptide presented in the context of self-MHC. Recent
evidence also suggests that complement activation might regu-
late B-cell antibody production and T-cell responses.
Goldstein and colleagues (102) were first to report a critical
role for a TLR signaling pathway in allograft rejection. Com-
pared with wild-type mice, skin allograft rejection was downregu-
lated in mice deficient in MyD88, a key TLR signaling molecule.
Using the same approach, these investigators found decreased
skin graft rejection in TLR2/ mice but not TLR4/ mice. These
data show MyD88-dependent and -independent signaling is in-
volved in TLR-mediated allograft rejection, and demonstrate a
key role for TLRs in linking the innate and adaptive immune
response during rejection.
The role of polymorphisms in TLR4 in human lung allograft
rejection has been reported recently. Using polymerase chain
reaction allelic discrimination assays, specific TLR4 polymor-
phisms at Asp299 and Thr399 alleles in the recipient were associ-
ated with a lower incidence of rejection (29% rate of rejection
in TLR4 mutants vs. 56% rate of rejection in wild-type recipient)
(103). In contrast, no effect was seen with the 299/399 polymor-
phisms on rejection by donor genotype. There was also a trend
toward a significant delay in the time to first acute rejection in
TLR4 polymorphic recipients as compared with wild-type recipi-
ents. In a larger cohort monitored over a 3-year period, post-
transplant individuals with the 299 or 399 polymorphisms had a
significant reduction in rejection episodes (104).
One intriguing hypothesis that emerges from these studies is
that the failure of currently available, primarily T-cell–based
therapies to completely prevent rejection, particularly in the lung,
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might not reflect failure at the T-cell level, but failure to prevent
innate immune responses from activating T cells or other ac-
quired immune responses. Specifically, local activation of innate
immunity (through macrophage TLRs, complement, and other
innate effectors) might drive the alloimmune response toward
rejection despite the use of effective T-cell–based immunosup-
pression. The innate response to pathogens, especially viruses, may
also be important because community-acquired viral infections
have been reported to be associated with BOS (105). However,
the molecular and cellular mechanisms that regulate the re-
sponse to microbes in the transplanted lung are in need of more
in-depth investigation.
Immunosuppressants used to prevent rejection suppress both
humoral and T-cell–mediated immunity. Thus, these patients
are more dependent on innate immunity to prevent and clear
potential pathogens. Therefore, other key effectors of lung in-
nate immunity, including alveolar macrophages (AMs), and the
collectins, such as surfactant proteins SP-A and SP-D (106, 107),
assume a critical role in host defense against invading pathogens.
AMs bind, phagocytose, and kill pathogens by producing reac-
tive oxygen/nitrogen intermediates (108), such as NO (109), and
trigger specific immunity by presenting antigen to T lymphocytes
(110). SP-A induces opsonization of pathogens by binding man-
nose and N-acetylglucosamine residues on microbial cell walls
(111), which enhances their attachment and phagocytosis by
AMs via specific and nonspecific receptors (112–118). SP-A also
induces AM chemotaxis and killing that stimulate release of
reactive oxygen intermediates, such as NO (107, 118). Therefore,
in addition to its well defined effects in downregulating AM
function, in response to infection, SP-A can function as an opso-
nin-enhancing, AM-mediated killer of pathogens.
Homeostasis of the lung microenvironment is altered dramat-
ically in the transplant recipient. For example, although SP-A
decreases NO production in AMs obtained from the BAL of
normal volunteers, SP-A significantly increased NO production
in 50% of AMs from transplant patients (109). Thus, SP-A ap-
pears to turn on the innate immune response in the presence
of inflammation and infection while suppressing inappropriate
activation of AMs in the normal lung. This has significant impli-
cations in the transplant setting where inappropriate release of
NO by AMs could account for lung pathology commonly ob-
served in these patients. Further complicating this issue are data
showing that nitration of SP-A limits its effectiveness, and ni-
trated proteins are increased markedly in BAL fluid from lung
allograft recipients (119). These reports show a complex relation-
ship between AMs and SP-A in the context of normal homeo-
static mechanisms and regulation of local innate immunity in
the allograft lung. However, the extent of SP-A nitration in
the alveolar spaces in transplanted lungs is not known, and the
potential effects of commonly used immunosuppressants on
SP-A and AM biology are largely unknown. Further research
is needed to determine if targeting specific innate immune recep-
tors/pathways or mediators of innate immunity effectively re-
duces allograft rejection and improves transplant outcomes. Fi-
nally, more studies are required to discern how innate immune
responses affect acquired immunity in the transplant recipient.
Chronic Allograft Dysfunction: OB/BOS Markers,
Mechanisms, Potential Therapies
Long-term survival rates for lung transplant recipients are con-
siderably lower than those observed in kidney, heart, and liver
recipients. This is due both to the poorer early survival rate and
to the development of chronic rejection manifest clinically as
BOS. This rejection is defined by progressive airflow obstruction
and deterioration of graft function (70). BOS is often associated
with a specific histologic lesion, OB, which is characterized by
Figure 3. Venn diagram of airway dysfunction after lung transplanta-
tion. Schematic representing the relative caliber of the airways, which
often presages the fate of lung transplant recipients. Many patients post-
transplant will develop airflow obstruction as measured by pulmonary
function testing (PFT). This is sometimes related to infection, but often
due to development of bronchiolitis obliterans syndrome (BOS). Often,
but not always, BOS is associated with histologic demonstration of
obliterative bronchiolitis (OB). (Courtesy of Marshall Hertz, M.D., Uni-
versity of Minnesota.)
inflammation and fibrosis of small airways (120). On a conceptual
basis, BOS and OB represent progressive loss of the cross-section
of the airways in the transplant patient (Figure 3).
Current therapies for OB/BOS are sometimes able to slow or
arrest disease progression; however, recovery of lost lung function
is unusual (121). Therefore, identification of reliable, reproduc-
ible, and noninvasive risk biomarkers for prevention and preclin-
ical detection of OB/BOS are important goals. Acute rejection
histology, characterized by perivascular and peribronchiolar
lymphocytic inflammation, has repeatedly been identified as a
major risk factor for OB/BOS (122). However, putative markers
of acute rejection, such as profiles of cellular activation (123) or
cytokine levels in BAL fluid observed during acute rejection
(124), are not reliable indices of OB/BOS. Markers of granulo-
cyte activation in BAL fluid have also been identified before or
concurrently with the development of OB/BOS (125, 126). In
addition, profibrotic cytokines have been identified in BAL fluid
from these patients (127, 128).
Gimino and colleagues (129) performed analyses of gene
expression in BAL and peripheral blood mononuclear cells from
lung transplant recipients with acute rejection and with no rejec-
tion. Two-dimensional hierarchic clustering based on the 135
most overexpressed genes in the acute rejection samples grouped
all acute rejection samples into one cluster, and the majority of
the nonrejection samples into a second cluster. Genes that were
upregulated in the acute rejection group included the following:
genes previously known to be involved in acute rejection, im-
mune-response genes with an unknown role in rejection, genes
not known to have a role in rejection, and genes of unknown
function. Gene expression patterns of peripheral blood mononu-
clear cells are markedly different than those of BAL cells. Tracking
the evolution of gene expression patterns in subjects who develop
OB/BOS may provide valuable clues to pathophysiology and
elaboration of therapeutic strategies for intervention.
Protein biomarkers of chronic rejection have been identified
using archived BAL fluid from lung transplant recipients whose
clinical outcomes are now known (129). Human neutrophil pep-
tides 1–3, members of the -defensin family of peptides, have
been associated with development of BOS, independent of epi-
sodes of acute rejection or cytomegalovirus (CMV) and fungal
infections. Identification of other protein biomarkers in BAL fluid
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of lung transplant recipients that will predict subsequent develop-
ment of BOS would be of value.
The important role of alloantigen-independent factors in the
development of BOS is underscored by the observation of an
association between gastroesophageal reflux disease and the de-
velopment of BOS (130, 131), and the recent observation of an
association between the presence of bile acids in BAL fluid and
the development of BOS (132).
BOS is a diagnosis of exclusion, because acute rejection and
infection can also cause airflow obstruction. Thus, invasive maneu-
vers like transbronchial biopsy and BAL are usually indicated for
establishing the diagnosis. Currently, therapy for new-onset BOS
usually starts with augmenting or altering the patient’s immuno-
suppressive regimen (121, 133, 134). Because methotrexate has
been used in patients with recurrent acute rejection (135), it has
been used to treat BOS. Photopheresis therapy has been advo-
cated by some centers to treat patients with BOS, but there are
limited reports documenting its efficacy (136).
Gerhardt and colleagues (137) reported that five of six pa-
tients with BOS had significant improvement in pulmonary func-
tion with oral azithromycin therapy, suggesting a potential role
for azithromycin in lung transplant recipients. Patients with cystic
fibrosis experienced clinical improvement and fewer exacerba-
tions on maintenance azithromycin therapy (138–140). Macro-
lide antibiotics exert both antiinflammatory and nonbactericidal
antimicrobial effects (141–143). In a retrospective analysis of more
than 200 lung transplant recipients, Johnson and colleagues (144)
demonstrated a strong association between the use of statins to
control hypercholesterolemia, and freedom from the develop-
ment of BOS. Other effects of the HMG coreductase inhibitors
other than their cholesterol-reducing properties have been al-
luded to above, and statins have been shown to reduce lung IRI
(145). These and other treatment strategies would be potential
candidates for multicenter prospective clinical trials to establish
efficacy and delineate mechanisms of action.
In summary, the current paradigm of T-cell–based allorecog-
nition driving the development of acute lung rejection and BOS
is built, in part, on an understanding of alloimmunity acquired
through studies of other solid organ transplants. However, this
model does not adequately explain why acute and chronic rejec-
tion rates are dramatically higher in lung transplant recipients
as compared with other solid organ transplant recipients. Fur-
thermore, the effect of the unique and constant environmental
exposures in the lung and the role of recurring infections (both
endogenous, such as CMV, and exogenous, including bacterial
and fungal) on immune activation is likely important. Similarly,
the central role of AMs and innate immunity in pulmonary host
defense must also be considered.
INFECTION AND REJECTION
The role of infection in lung transplantation is well established.
CMV causes both latent infection in seropositive individuals
and invasive infection in the transplant recipient. CMV and other
viruses (respiratory syncytial virus, influenza, Epstein-Barr virus)
contribute not only to direct graft injury (i.e., pneumonia) but also
to an array of indirect effects, including predisposition to other
opportunistic infections (e.g., pneumocystis and Aspergillus infec-
tions) and to the risk of rejection and post-transplant malignancy.
CMV seropositivity in the donor or recipient is associated with
an increased risk of death (146–148). Viral infections, including
CMV, respiratory syncytial, parainfluenza, and adenoviral infec-
tions, are risk factors for BOS (discussed below) (105, 149–152).
Allorejection may be enhanced by coinfection of grafts by viral
or other pathogens through a process termed “heterologous im-
munity.” This is believed to involve upregulation of MHC anti-
gens and presentation of novel or cross-reacting epitopes on the
surfaces of infected cells (153–155). In general, the mechanisms
by which infection impacts the outcomes of lung transplantation
remain poorly defined and are important areas for future investi-
gation. The role of viral infection in the development of malig-
nancy (Epstein-Barr virus and post-transplant lymphoma) is be-
ginning to be explored. Better models of infection and malignancy
in lung transplantation should be developed.
IMMUNOSUPPRESSION
The discovery of the calcineurin inhibitor cyclosporine A ush-
ered in the modern era of successful extrarenal solid organ trans-
plantation (156). However, it is also true that current drugs used
as immunosuppressants are (1) relatively nonspecific regarding
donor/recipient interactions, (2) toxic, and (3) cause problems
that contribute to morbidity and mortality after solid organ trans-
plant, both because of specific organ toxicity (especially renal)
and the increased risk of opportunistic infections from the “broad”
immunosuppressive strategies used to prevent rejection (157).
The optimal immunosuppression regimen for lung transplant
recipients is unknown. Although there is some variability among
programs, most use “triple immunosuppression” consisting of
a calcineurin antagonist (cyclosporine or tacrolimus), an anti-
metabolite (azathioprine or mycophenylate), and corticosteroids
(158). The danger of the early use of rapamycin in lung recipients
has been documented because of its antifibrotic effects on bron-
chial wound healing (159). However, the same antifibrotic effects
may make this a useful agent to arrest progression of BOS.
There is considerable variability in the use of induction therapy
with antilymphocyte agents (158), but there are some encourag-
ing early data supporting the use of alemtuzumab in a small
number of lung transplant recipients with short follow-up periods
(160). The lung is ideally suited to the strategy of “local” immu-
nosuppressive therapy because of the ability to use the airway
as a conduit for medications. Aerosolized cyclosporin A has been
used to treat refractory acute rejection, and may permit reduction
of systemic drug levels (161).
Recent advances in genomics may allow for in-depth analyses
to determine optimal immune suppression. Genetics may influ-
ence the nature of the immune response among individuals. Simi-
larly, the genetic makeup of patients may alter the efficacy or
side-effect profiles of pharmacologic agents. Genetics influence
drug efficacy and pharmacokinetics in individuals through vari-
ability uptake and metabolism of medications. This concept,
known as pharmacogenomics, has been shown to have a major
impact in determining which medications may be effective in
individual patients treated with cancer chemotherapeutics (162).
However, the application of pharmacogenomics in solid organ
transplantation has not yet been reported. The possibility exists
that immunosuppressive regimens may be tailored for an individ-
ual patient to minimize toxicities and to address the individual’s
needs for specific antirejection therapies for the organ trans-
planted. As such, pharmacogenomics is a field requiring more
in-depth study in organ transplant recipients.
STRENGTH THROUGH NUMBERS
Currently, the small number of lung transplant procedures per-
formed at a relatively large number of centers is a serious obsta-
cle to collection of useful information concerning the biology of
the transplanted lung. Accordingly, establishing a network of
centers to facilitate scientific investigations should lead to im-
provement in outcomes for the transplant recipient.
Such a network would also facilitate uniformity in classifica-
tion of donor quality, immunosuppression strategies, standard-
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TABLE 1. GENERAL RECOMMENDATIONS OF THE WORKING
GROUP
1. Establish a multicenter collaborative network to enhance the standards of
clinical protocols; understand the disease of BOS, including a lung tissue
repository to assist in the characterization of the disease; and conduct clinical
trials.
2. Increase use of the present donor pool of lung organs (use in United States
is about 15% vs. 30 to 40% in European countries). Public policy issues
should increase awareness of organ donation, and explore the feasibility of
expanding the donor pool by use of lungs from non–heart-beating donors.
3. Develop methods to better assess quality of donor lungs before transplanta-
tion and to reliably predict graft failure.
4. Assess new strategies for creating tolerance in the recipient and optimizing
immunosuppression using pharmcogenomic methods.
5. Identify better biomarkers, based on proteomic and genomic approaches,
that will predict BOS before patient symptoms and/or irreversible loss of
pulmonary function develop.
6. Investigate methods to ameliorate ischemia/reperfusion injury in the allograft
lung.
7. Develop models to investigate the roles of infection, both viral and nonviral,
and the molecular mechanism that regulates innate immunity in the patho-
genesis of lung injury after transplantation.
8. Support and promote research into the whole spectrum of graft dysfunction:
primary failure, acute rejection, and BOS. This would focus on innate and
adaptive immunity and the emerging awareness that autoimmunity is in-
volved in the rejection response.
9. Develop novel approaches for immune suppression and tolerance induction
to lung allografts.
10. Continue to assess and develop relevant animal models that reflect human
illness.
Definition of abbreviation: BOS  bronchiolitis obliterans syndrome.
ization of terminology of graft failure and development of BOS,
and standardization of tissue and specimen collection and prepa-
ration. The development of this network would provide a forum
for consistent data collection and an opportunity for lung trans-
plant recipients to participate in multicenter clinical trials to
properly evaluate therapeutic strategies to treat OB/BOS that
have been promulgated with inadequate evidence-based sup-
port.
CONCLUSIONS
Lung transplantation is a relatively new field aimed at the treat-
ment of end-stage lung failure. The challenges facing the lung
transplant patient and medical teams are only beginning to be
addressed, but are important areas for basic and clinical investi-
gation. Strategies are needed to increase the number of organs
available for transplantation and to reduce graft destruction
mediated by infection, inflammation, and immunity in the post-
transplant period. The condition of the donor lung in the pre-
transplant period is inextricably linked to function post-trans-
plantation. Accordingly, developing techniques that lead to tol-
erance of the allograft, the Holy Grail of transplantation for all
organs, is the ultimate goal of these approaches. It is the hope
of the working group that the recommendations listed in Table 1
will greatly improve our understanding of lung transplant biol-
ogy, and ultimately will lead to decreased morbidity and mortal-
ity for our patients.
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